Watertown-based Vigil Neuroscience has agreed to be acquired by drug giant Sanofi in a deal worth approximately $600 million. The transaction is expected to close in the third quarter of 2025. Vigil is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases using microglia, the sentinel immune cells of the brain. Iluzanebart, Vigil’s lead […]

GSK has agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready, potential best-in-class, investigational drug for steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totaling $800 million. Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of fibroblast […]

Bain Capital Real Estate is teaming with Botanic Properties, a real estate investment and development firm focused on the biomanufacturing industry, to acquire 45 Crosby Drive in Bedford. The investment is being made by GenesisM, a specialized real estate platform dedicated to developing purpose-built biomanufacturing facilities. Financial terms of the purchase were not disclosed. The […]

Verve Therapeutics has won FDA clearance of its Investigational New Drug (IND) application for VERVE-102 for the treatment of patients with familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density […]

Sionna Therapeutics, a Waltham biotech targeting cystic fibrosis, has closed its IPO, raising about $219 million. Sionna is a clinical-stage company seeking to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for […]

Alnylam delivered a one-two punch in March, growing its portfolio of FDA-approved RNAi therapies with the addition of Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM) and Qfitlia (fitusiran) for hemophilia. Qfitlia (fitusiran) is the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, and […]

Biogen has announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s R&D and technical operations teams alongside its global and North American commercial organizations into a co-located […]

bluebird bio has entered into a definitive agreement to be acquired by private-equity firms Carlyle Group and SK Capital Partners in collaboration with a team of highly experienced biotech executives in a deal worth up to $96 million. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will […]

Stoke Therapeutics has entered into a collaboration with Biogen on the development and commercialization of zorevunersen, a potential first-in-class treatment for a form of epilepsy known as Dravet syndrome. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Upon closing of the transaction, Stoke will […]